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Abstract: Dengue fever, which is a disease caused by the dengue virus (DENV), is a major unsolved 
issue in many tropical and sub-tropical regions of the world. The absence of treatment that effec-
tively prevent further viral propagation inside the human’s body resulted in a high number of 
deaths globally each year. Thus, novel anti-dengue therapies are required for effective treatment. 
Human hexokinase II (HKII), which is the first enzyme in the glycolytic pathway, is an important 
drug target due to its significant impact on viral replication and survival in host cells. In this study, 
23.1 million compounds were computationally-screened against HKII using the Ultrafast Shape 
Recognition with a CREDO Atom Types (USRCAT) algorithm. In total, 300 compounds with the 
highest similarity scores relative to three reference molecules, known as Alpha-D-glucose (GLC), 
Beta-D-glucose-6-phosphate (BG6), and 2-deoxyglucose (2DG), were aligned. Of these 300 com-
pounds, 165 were chosen for further structure-based screening, based on their similarity scores, 
ADME analysis, the Lipinski’s Rule of Five, and virtual toxicity test results. The selected analogues 
were subsequently docked against each domain of the HKII structure (PDB ID: 2NZT) using Auto-
Dock Vina programme. The three top-ranked compounds for each query were then selected from 
the docking results based on their binding energy, the number of hydrogen bonds formed, and the 
specific catalytic residues. The best docking results for each analogue were observed for the C-ter-
minus of Chain B. The top-ranked analogues of GLC, compound 10, compound 26, and compound 
58, showed predicted binding energies of −7.2, −7.0, and −6.10 kcal/mol and 7, 5, and 2 hydrogen 
bonds, respectively. The analogues of BG6, compound 30, compound 36, and compound 38, showed 
predicted binding energies of −7.8, −7.4, and −7.0 kcal/mol and 11, 9, and 5 hydrogen bonds, while 
the top three analogues of 2DG, known as compound 1, compound 4, and compound 31, showed 
predicted binding energies of −6.8, −6.3, and −6.3 kcal/mol and 4, 3, and 1 hydrogen bonds, sequen-
tially. The highest-ranked compounds in the docking analysis were then selected for molecular dy-
namics simulation, where compound 10, compound 30, and compound 1, which are the analogues 
of GLC, BG6, and 2DG, have shown strong protein-ligand stability with an RMSD value of ±5.0 A° 
with a 5 H bond, ±4.0 A° with an 8 H bond, and ±0.5 A° with a 2 H bond, respectively, compared to 
the reference molecules throughout the 20 ns simulation time. Therefore, by using the computa-
tional studies, we proposed novel compounds, which may act as potential drugs against DENV by 
inhibiting HKII’s activity. 
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Dengue is a major unsolved problem, complicated by factors including sequential 
infection with different dengue serotypes, increased populations, unplanned urbaniza-
tion, and uncontrolled population increase of the leading vector, Aedes aegypti. The conse-
quences of these factors are a resurgence in dengue epidemics and the introduction of 
dengue hemorrhagic fever and dengue shock syndrome to previously unaffected regions 
[1–3].  
The clinical manifestation of dengue has a broad range of symptoms, from a minor 
influenza-like pattern, which is associated with high fever, vomiting, loss of appetite, se-
vere headache, myalgia, and arthralgia, to a severe life-threatening illness characterized 
by plasma leakage, thrombocytopenia, hemorrhage (dengue hemorrhagic fever), and the 
potential to develop shock [4,5]. Global incidence of dengue has increased dramatically in 
recent years, with 390 million infections occurring annually. Of these cases, 96 million 
cases manifest clinically and 3.9 billion are at risk of dengue infection [6]. More than 70% 
of cases occur in the South-East Asia and Western Pacific regions [6]. According to the Pan 
American Health Organization (PAHO), approximately 3 million dengue cases are cur-
rently being reported in America alone, including 68 fatal cases. This represents a 42% 
increase compared to the previous year [7]. The incidence of dengue has also substantially 
increased in Asia.  
Dengue infection is caused by the dengue virus, which is a single-stranded RNA vi-
rus belonging to the Flaviridiae family. It is transmitted to humans from female mosqui-
toes of the Aedes genus, principally A.aegypti, through a single bite [6,8,9]. The positive-
sense viral RNA, which has a length of approximately 11 kb, encodes three structural pro-
teins (capsid, pre-membrane, and membrane) that help form the virion and seven non-
structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) that aid in viral rep-
lication [10]. Dengue virus has four distinct antigenic serotypes: DENV-1, DENV-2, 
DENV-3, and DENV-4. Sequential infection with multiple serotypes of the virus can result 
in a more severe form of the disease [11,12].  
Viruses are intercellular infectious agents that rely on the metabolic machinery of the 
host cell to survive and replicate. Several viruses, such as human cytomegalovirus 
(HCMV), herpes simplex virus 1 (HSV-1), hepatitis C virus, influenza A virus, human 
immunodeficiency virus type 1 (HIV-1), Kaposi’s sarcoma-associated herpesvirus 
(KSHV), and vaccinia virus (VACV) have been shown to cause extensive changes to the 
central carbon metabolic pathways of host cells during viral attack [13–15]. In recent years, 
Fontaine and colleagues have demonstrated how dengue virus can alter host metabolism 
by conducting intracellular metabolic profiling of mock-infected and dengue-infected pri-
mary human foreskin fibroblasts (HFFs) at different time points [15]. The experimental 
data suggested that central carbon metabolism, specifically the glycolytic pathway, is sig-
nificantly disrupted during dengue virus infection. In dengue virus infected cells, glucose 
consumption was increased, as was expression of glucose transporter 1 (GLUT1) and hu-
man hexokinase II (HKII), which are important regulating enzymes in the glycolytic path-
way [15]. In the presence of oxygen, normal cells metabolize glucose via glycolysis to pro-
duce ATP through oxidative phosphorylation within the mitochondria. In tumor and can-
cer-infected cells, glucose is metabolized in a different way from normal cells with pro-
duction of ATP from aerobic glycolysis, in a phenomenon called the “Warburg effect.” In 
addition, normal cells require energy (ATP or GTP), which are also building block com-
ponents to ensure specific cell functions, while tumor and cancer cells must replicate all 
their cellular components, thus, increasing their need for a biosynthetic building block 
(nucleotides, amino acids, and lipids). The main attribute of this metabolic changes is an 
increase in the glucose uptake by the cell. Extensive studies have postulated that virus-
infected cells have the same Warburg-like phenomena where the key enzyme of glycolytic 
pathway, HKII contributes to enhanced glucose consumption in infected cells [16–19]. 
HKII is a rate-limiting enzyme of the glycolytic pathway that assist in increasing glucose 
consumption in the virus-infected cell. Hence, HKII has been chosen as a potential drug 
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target. Fontaine and colleagues have also reported that glucose consumption tremen-
dously increased during dengue viral infection, where glucose is metabolized via the host 
glycolytic pathway and provides energy (ATP) as well as metabolites to a dengue-infected 
cell. Consequently, virus takes this metabolic change as an advantage and assists them-
selves to survive and replicate inside the host cell. It has also been proven that HKII en-
hanced glucose consumption in the infected cell, as it is the key enzyme of the glycolytic 
pathway, which served as a basis for the enzyme to be a target in antiviral therapy [20]. 
Several studies on other viruses such as the poliovirus, HSV-1 [21], HCMV [22], HSV [23], 
and HCV [24] have also been documented, highlighting that glycolysis is crucial for the 
viruses to survive and replicate inside a host cell, where HKII governs the pathway. 
Several experiments have shown that viral replication, as well as tumor cell prolifer-
ation, were positively correlated with glycolysis. This suggests that treatment with 2-de-
oxyglucose (2DG), which is a competitive antagonist of the glycolysis process, could in-
hibit viral replication [19,20]. 2DG is an analogue of glucose, in which two hydroxyl 
groups have been replaced by hydrogen atoms. This inhibits the production of glucose-6-
phosphate, ultimately inhibiting the glycolytic pathway [25]. 2DG has been suggested by 
several studies for treating cancer, alongside inhibiting dengue virus replication [26–28]. 
However, 2DG has shown toxic effects when used to treat patients [19,29]. Hence, it is 
vital to find new compounds that are similar to 2DG, but do not induce toxicity, as these 
could be valuable candidates for anti-dengue drug development. Nevertheless, 2DG has 
been used as a competitive inhibitor of glucose for HKII in various viral therapeutic re-
search, but, as previously shown, 2-DG has exhibited toxic effects on host cells [19]. Hence, 
the situation further urges finding potential inhibitors against HKII for the development 
of anti-dengue therapeutics. In addition to 2DG, both Alpha-D-glucose (GLC) and Beta-
D-glucose-6-phosphate (BG6), which are the substrate and product of HKII, respectively, 
were used as reference molecules for rational drug design.  
In this study, we report the identification of small molecules, which have the poten-
tials to be developed into safe and effective anti-dengue drugs. We first conducted a lig-
and-based drug design experiment by screening compounds similar to those described 
above. Subsequently, a series of docking and scoring experiments were conducted, which 
were followed by structure-based screening using the crystal structure of human HKII 
(PDB ID: 2NZT). These compounds were then subjected to virtual toxicity testing. Finally, 
the best-performing compounds were selected for Molecular Dynamics (MD) simulation 
analysis. 
2. Materials and Methods 
2.1. Ligand-Based Screening 
2.1.1. Identification of Lead Molecules and Analogues 
In this study, ligand-based screening has been performed to filter drug-like com-
pounds based on its query molecules with shape similarity, physiological properties, and 
toxicity from enormous compound libraries. Ligand-based screening provides a set of 
structurally-diverse ligands that bind to a receptor, where the approach of this screening 
is based on searching for molecules with a shape similarity to that of known actives, as 
such molecules will fit the target's binding site [30]. Three different lead molecules Alpha-
D-glucose (GLC), Beta-D-glucose-6-phosphate (BG6), and 2-Deoxyglucose(2DG) have 
been used as query molecules for initial pharmacophore screening. The common struc-
tural features of GLC, BG6, and 2DG have a glucose chain with six carbon atoms. Moreo-
ver, the functional feature of these query molecules (GLC, BG6, and 2DG) is possessing 
inhibitory effect to human HKII protein. It has been proven that, at a high concentration 
(up to 5 µM), GLC shows an inhibitory effect on HKII, while BG6 itself is an inhibitory 
product of HKII, while 2DG is a well-known inhibitor of HKII [17,29,31]. 
The structure data file (SDF) of GLC, BG6, and 2DG (with PubChem ID CHEBI: 10822 
ID CHEBI: 17925 and ID CHEBI: 17719, as well as molecular formula C6H12O5 C6H12O6 
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and C6H13O9P) were extracted from PubChem (https://pubchem.ncbi.nlm.nih.gov/) to 
screen for the analogues by using Ultrafast Shape Recognition with CREDO Atom Types 
(USRCAT) available at http://usr.marseille.inserm.fr/. A total of 300 compounds, where, 
for each query of molecules, 100 similar hits have been countenanced from the USRCAT 
program. All predicted molecules ranked based on score zero (0) to one (1) score, where 
a compound with a score near to one indicated greater similarity toward its respective 
query molecule. Furthermore, a total 165 hits out of 300 has been screened based on Ab-
sorption, Distribution, Metabolism and Excretion (ADME) analysis, a toxicity test, and a 
Lipinski’s Rule of Five. Later, selected compounds were screened through a structure-
based approach and, finally, were analysed through molecular dynamics simulation stud-
ies. 
2.1.2. ADME Analysis 
Physiochemical properties such as absorption, distribution, metabolism, and excre-
tion for all compounds were predicted from the SwissADME website 
(www.http://www.swissadme.ch/index.php), prior to a docking study. Structure data file 
(SDF) for each compound was used to obtain ADME values. All selected compounds ful-
filled the benchmarks of ADME analysis. 
2.1.3. Toxicity Test 
In a drug design process, the prediction of compound toxicity is crucial to identify 
non-toxic compounds. In this experiment, we used ProTox-II (www. http://tox.char-
ite.de/protox_II/) to determine the non-toxicity of selected compounds. The SDF format of 
each compound was converted into a molecular data file (MDL Molfile) using Open Bable 
software. Various toxicity end points such as acute toxicity, hepatotoxicity, cytotoxicity, 
mutagenicity, and immunotoxicity have been tested to predict the level of toxicity of each 
compound. In ProTox-II, toxic levels were classified in six different forms, Class-I to Class-
VI, based on a range of lethal dose (LD50) values, where Class-I determines the toxic com-
pound, while Class-VI determines a non-toxic compound. 
2.2. Structure-Based Screening 
2.2.1. Retrieval and Structural Preparation of the Protein 
HKII is a homodimer protein with highly similar N and C terminal domains that 
together form half of the protein. The crystal structure of HKII (PDB ID: 2NZT) was re-
trieved from the Protein Data Bank website (https://www.rcsb.org/). The native structure 
of the protein was complexed with a heteroatom, a water molecule, and an unknown 
unique ligand (UNX), which are crucial to be removed to ensure good protein-ligand in-
teraction. The water molecule might deform the binding site residues as well as the inter-
actions between protein-ligand atoms. On the other hand, the heteroatom and unknown 
ligand have to be removed due to docking of the selected ligand and to facilitate a smooth 
molecular docking process. Structural visualization was conducted using PyMOL soft-
ware. 
2.2.2. Molecular Docking 
Molecular docking is usually referred to as protein-ligand binding. The aim of dock-
ing is to understand molecular recognition, a favourable binding pose, and binding affin-
ity of ligand toward the 3D structure of the receptor protein. The protein structure was 
prepared by protein optimization and energy minimization by adding hydrogen atoms, 
as well as removing an existing ligand from the active site. The known ligands (GLC and 
BG6) were removed for a re-docking purpose, where the active site of the protein structure 
is typically being validated by re-docking experiments [32–34]. The ligands (GLC and 
BG6) were extracted from native protein-ligand complexes to evaluate the conformation 
and, subsequently, docked back into the protein to validate the docking location. In this 
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case, we scrutinized the native structure of HKII using PyMOL and observed that there is 
a cleft inside both N-terminal and C-terminal domain in the protein, where two known 
ligands (BG6 and GLC) were located in parallel. The selected compounds and their query 
molecules were docked inside the cleft sequentially. It should be noted that only the N-
terminal domain was used to conduct the docking process because the N-terminal domain 
regulates the stability of the whole enzyme, in contrast with the C-terminal domain 
[35,36]. Recently, Nawaz and colleagues have reported that the human hexokinase II is 
overexpressed in tumours and predominantly found on the outer mitochondrial mem-
brane where its N-terminus initiates and maintains the tumorigenesis. They further crys-
talized and generated the protein’s structure using MODELLER [36,37]. However, the cat-
alytic residue of human hexokinase II has not yet been publicly available. Hence, it was a 
challenge to find the active site residues of HKII. In this experiment, we scrutinized the 
catalytic residues around the cleft of HKII, where the known ligands (GLC and BG6) were 
bound using MGLTools (version 1.5.7), which were further validated by re-docking pro-
cesses. In this research, we used the AutoDock Vina program that significantly improved 
the average accuracy of the binding mode predictions. In the Vina script, all information 
must be included such as grid box size (Box size: 26 ×24 × 22 A°), grid box centre (X = 
43.567, Y35.439 Z = 36.27), and measurement of space (1.000), where the defined grid box 
encompasses the protein binding site to do sequential docking of all selected ligands. The 
ligands were prepared by adding a non-polar hydrogen atom using Avogadro. Since Au-
toDock Vina can only accept a Protein Data bank, Partial Charge (Q), and atom Type (T) 
format (PDBQT), the PDBQT format of the HKII protein, and all grid box information 
were occupied using MGLTools, while the SDF files of all ligands were converted to a 
PDBQT file using OpenBable software. 
2.3. Molecular Dynamics Simulation 
Molecular dynamics simulation has been widely used to scrutinize the behaviour of 
molecules at an atomic level, in order to understand the structure and interactions be-
tween a protein and a ligand molecule in a period of time. We set up molecular dynamics 
simulation of selected compounds against HKII by using GROMACS version 5, where the 
.pdb format of protein and selected compounds from molecular docking were converted 
to a GROMACS file format to be implemented in the MD simulation. Atomic interactions 
were calculated with a gromos96 54a7 force field and all systems were solvating in a cubic 
box with a simple point charge (SPC) pre-equilibrate water system. Ligand topology files 
were extracted from the Automated Topology Builder (ATB) (https://atb.uq.edu.au) 
server since GROMACS does not generate a ligand topology file. We used standard cut-
off 1.0 nm for short-range coulomb interaction, where statistical and energy data are 
stored for every 10 steps. The v-rescale and Berendsen weak coupling algorithm were 
used to control temperature and pressure, respectively, during the simulation process. 
The water equilibration around the protein-ligand complex is crucial to avoid unnecessary 
exaggeration of the complex when the MD simulation has started. In order to avoid this 
problem, we performed an equilibration run for 100 ps, where all heavy atoms were re-
strained at their start position. Finally, 20 ns constrained MD simulation was performed 
for each selected protein-ligand complex. All bond lengths, including the hydrogen atoms 
were constrained by the LINCS algorithm. After simulation has completed, we viewed 
the trajectory by using VMD and analysis such as RMSD, distance between protein and 
ligand throughout the simulation, and formation of the hydrogen bond, which were car-
ried out using Xmgrace software. The virtual screening workflow is presented in Figure 
1. 




Figure 1. The virtual screening work flow. The process begins with ligand-based screening, selec-
tion of drug-like molecules by Lipinski’s Rule of Five, ADME analysis, toxicity analysis, docking, 
and Molecular Dynamics simulation. 
3. Results and Discussion 
3.1. Ligand-Based Screening 
3.1.1. Identification of Analogues 
In pharmaceutical research, in silico screening has become prominent day-by-day. It 
is a computer-based method divided into ligand-based screening and structure-based 
screening. The former is the initial stage of virtual screening, which is the most exoteric 
approach for drug discovery and lead optimisation. The spotlight of this technique is to 
compare molecular similarity with known and unknown fractions [32,33]. Ligand-based 
screening exploits key structural and physiochemical properties of ligands and target to 
enable the screening of active compounds, while structure-based screening most widely 
used for molecular docking by exploiting the three-dimensional (3D) structure of the tar-
get protein and predicting the preferred protein-ligand binding pose through the scoring 
function [30,33,38]. In this work, USRCAT (Ultrafast Shape Recognition with CREDO 
Atom Type) program has been used to screen similar compounds of Alpha-D-glucose 
(GLC), Beta-D-glucose-6-phosphate (BG6), and 2-deoxyglucose (2DG) against HKII, 
where GLC and BG6 are the substrate and product of HKII, respectively, while 2DG is a 
known inhibitor of HKII. USRCAT is a publicly-accessible web tool, which is able to 
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screen 50 million conformers per second. USRCAT is an extended version of USR (Ultra 
shape recognition) algorithm, which is improved with the CREDO database, where users 
are able to find an enormous chemical component ranging from a natural product to drug-
like molecules as well as solvent molecules and ions. USRCAT is an advanced version of 
UFSRAT in terms of having high capability to differentiate similar molecules at an atomic 
level and intended to discriminate between long chain-like molecules, such as heteropep-
tides and long alkayl chains [39]. The USRCAT algorithm is based not only on shape sim-
ilarity but also considers geometrical distribution of atoms such as all atoms, a hydrogen 
bond donor, and acceptor atoms, as well as aromatic atoms [39]. 
In this study, 23.1 million molecules were screened and a total of 300 most similar 
compounds were obtained from USRCAT for all of the reference molecules (2DG, GLC, 
and BG6). Thus, specifically, each query has 100 similar compounds aligned into the 
hits.csv file along with similarity scores, physicochemical properties, and the vendor’s in-
formation. Similarity was evaluated based on the scoring function ranging from 0–1, 
where zero and one indicates minimum and maximum similarity, respectively. As men-
tioned above, the USRCAT score zero indicates the least similar compounds, while those 
closer to one reflects a much closer resemblance toward the reference molecule. Based on 
these findings, a total of 165 compounds out of 300 similar hits for each query molecule 
were chosen and their physiological properties were obtained from the ZINC database. 
The ZINC database contains 727,842 purchasable compounds from various suppliers 
(ChemBridge, ChemDiv, Ryan, Asinex, Sigma-Aldrich, Maybridge, Specs, Comgenex, 
and Otava) in which 494,915 are Lipinski subjacents. Based on the similarity scores, the 
three top-ranked compounds that resembled each of the query molecule are shown in 
Table 1-3, as their ranking scores ranged from 0.946 to 0.913, 0.817 to 0.812, and 0.806 to 
0.751 for GLC, BG6, and 2DG, respectively. All three compounds, which are analogues of 
2DG, GLC, and BG6, which have been selected for the subsequent studies, obeyed the 
Lipinski’s Rule of Five in terms of their physiological parameters, hydrogen bond donors 
˂5, hydrogen bond acceptor ˂10, molecular weight under ˂500 g/mol, and a partition co-
efficient logP ˂ 5 with no violation [40]. The mentioned parameters related to the 
Lipinski’s Rule of Five are presented in Tables 1 to 3. Compounds 10 to 58, which are 
similar conformers of GLC possess MlogP values ranging from −2.15 to −1.93, and drug-
likeness from 0.14 to −0.01 (Table 1). Moreover, the top three similar hits of BG6, com-
pounds 30 to 38 have MlogP values from −4.02 to −3.84 and drug-likeness from 0.89 to 
−1.08 (Table 2). Drug-likeness is the preliminary concept of drug design and its value is 
usually estimated from the compound’s molecular structure standardized between -0.4 
and 5.6, whereby it indicates whether the compound has drug properties or not. Since our 
findings were optimized with respect to the drug-likeness parameter and the adherence 
to the Lipinski’s Rule of Five, most of the compounds fulfilled all the criteria. The drug-
like properties of 2DG corresponded to the MlogP values between 0.06 and −0.08, and 
drug-likeness between -0.64 and −1.16 (Table 3). It is noteworthy to note that, although the 
same scores were obtained from the USRCAT program, these compounds are structurally 
different and contain different atom types. The Rule of Five provides insights for the anal-
ysis of the molecular properties and structural features of every compound, which is im-
portant for drug pharmacokinetics in a human’s body, including their absorption, distri-
bution, metabolism, and excretion (ADME) [41]. 
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Table 1. Similarity scores and Lipinski’s values for GLC and its analogues, as obtained from USRCAT. 
Compound 
Number 













 5/6 180.156 −3.21 0.01 
10 3,956,760 
 
0.946 4/5 182.147 −2.15 0.14 
26 16,159,409 
 
0.933 4/5 182.147 −2.15 0.09 
58 3,809,846 
 
0.913 4/5 182.147 −1.93 −0.01 
Table 2. Similarity scores and Lipinski’s values for BG6 and its analogues, as obtained from USRCAT. 
Compound 
Number 










 6/9 260.135 −3.64 −0.20 
30 4,403,145 
 
0.817 6/8 238.192 −3.84 0.89 
36 4,530,268 
 
0.812 6/9 252.199 −4.02 0.72 
38 1,576,959 
 
0.812 6/8 238.192 −3.84 −1.08 
  
BioTech 2021, 2, FOR PEER REVIEW 9 
 
 
Table 3. Similarity scores and Lipinski’s values for 2DG and its analogues, as obtained from USRCAT. 
Compound 
Number 













 4/5 164.157 −1.95 −1.33 
1 86,652,948 
 
0.806 2/4 215.317 0.06 −0.64 
4 86,991,606 
 
0.796 2/4 213.301 −0.08 −1.16 
31 86,991,603 
 
0.751 2/4 213.301 −0.08 −1.16 
Computational methods are effectively used in pharmaceutical research to improve 
the drug discovery process. Ligand-based screening is one of the crucial parts of in silico 
drug design and several novel compounds have been invented through this process. 
Hence, considering the importance of a computational drug design method, it was 
adopted in the present study to discover the potential HKII inhibitors. Numerous success-
ful ligand-based screening investigations have been performed, aiming to identify poten-
tial inhibitors against dengue drug targets. In extant studies, dengue virus encoded non-
structural protein 3(NS3) was used as a drug target, and two known inhibitors, namely 
suramin and ivermectin, have been successfully identified through virtual screening and 
in vitro analysis, where researchers used a LOPAC compound library for inhibitor selec-
tion as well as vero-B and vero-E6 cell for an in vitro assay [42,43]. It is noteworthy to note 
that most of the research conducted to search for anti-dengue drugs have been conducted 
against viral replication proteins or viral envelop proteins, but our research focus is on a 
human protein as a drug target. There are numerous web-based programs available to 
implement this process, whereas, in this work, an online program, USRCAT, has been 
utilized, which was incorporated with a ZINC database. Lipinski’s Rule of Five functions 
as a filter to choose drug-like compounds based on their molecular property, including 
absorption, distribution, metabolism, and excretion. Selected compounds were chosen 
based on the similarity scores and drug-like criteria. 
3.1.2. Physiochemical Properties Analysis (ADME) 
ADME studies are crucial parts of any drug development program and essential for 
obedience with regulatory guidelines [41]. In this work, an acceptable range in the values 
of predicted physiochemical and pharmaceutical properties of selected compounds has 
been achieved, which includes absorption, distribution, metabolism, and excretion (Ta-
bles 4–6). The water solubility of a compound reflects the solubility of the molecule in 
water at 25 °C, where the threshold of the solubility is ˂0.05 log mol/L. The lipid-soluble 
drug is less well-absorbed than water-soluble ones. The Caco-2 permeability cell line is 
composed of human epithelial colorectal cells, which is widely used as an in vitro model 
of the human intestinal mucosa to predict the absorption of orally-administered drugs 
[44]. 
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The water solubility of a compound reflects the solubility of the molecule in water at 
25 °C. A lipid-soluble drug is less well-absorbed than water-soluble ones. The Caco-2 per-
meability cell line is composed of human epithelial colorectal cells, which is widely used 
as an in vitro model of the human intestinal mucosa to predict the absorption of orally-
administered drugs [44]. These models predicted the Caco-2 permeability values using a 
logarithm of the permeability coefficient (log cm/s) based on the 647 drug-like molecules. 
For the ADME predictive model, a high Caco-2 permeability value would be ˃0.90. Fur-
thermore, intestinal absorption is a primary site for absorption of a drug orally, where a 
less than 30% predated value is considered poor absorption while logKp ˃ –2.5 defines 
the low skin permeability. This predictive model was built using the measured free pro-
portion of 552 compounds in human blood (Fu), where the predicted value should be less 
than 2.81 log10−6 cm/s and logBB ˃ 0.3 as well as logPS ˃ 2 was considered to readily cross 
the blood brain barrier (BBB) and penetrate the central nervous system, respectively 
[41,44]. However, our findings successfully met the parameter of absorption for each 
query molecule and the selected analogues. 
Table 4. The ADME results of GLC and analogues. 








Water solubility log mol/L −1.377 −1.08 −1.005 −1.581 
Caco2 
permeability 




%(Absorbed) 21.51 59.553 59.79 59.316 
Skin 
Permeability 





logL/Kg 0.82 0.841 0.84 0.853 
BBB 
permeability 
logBB −0.943 −0.786 -0.9 −0.872 
CNS 
permeability 
logPS −3.636 −3.552 −3.552 −3.192 
Metabolism 
CYP2D6 Yes/No No No No No 
CYP1A2 Yes/No No No No No 
Excretion 
Oral Rat Acute 
Toxicity (LD50) 
mol/kg 0.626 0.535 0.535 0.534 
Renal OCT2 
substrate 
Yes/No No No No No 
The results (Tables 4–6) revealed that all compounds possess good water solubility, 
Caco2 permeability, human intestinal absorption, and skin permeability values. Greater 
values of these parameters denote that the compound could be better absorbed from the 
intestinal tract upon oral administration. Moreover, fraction unbound values (Fu ˂ 1) in-
dicate that the compounds exist in plasma at an unbound state and could efficiently travel 
through the cellular membrane. In addition, all compounds displayed negative penetra-
tion through the Blood Brain Barrier (BBB) and Central Nervous System (CNS), which 
means that these compounds do not cross the BBB and CNS (Tables 4–6). 
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Table 5. The ADME results of BG6 and analogues. 








Water solubility log mol/L −0.811 −1.753 −1.995 −1.753 
Caco2 permeability Log 10−6 cm/s −0.341 −0.104 −0.371 −0.104 
Intestinal absorption (human) %(Absorbed) 35.51 26.376 0 26.376 
Skin Permeability logKp −2.82 −2.744 −2.735 −2.744 
Distribution 
Fraction unbound (human) logL/Kg 0.716 0.79 0.886 0.232 
BBB permeability logBB −1.414 −1.032 −0.928 −1.032 
CNS permeability logPS −4.211 −3.46 −3.604 −3.46 
Metabolism 
CYP2D6 Yes/No No No No No 
CYP1A2 Yes/No No No No No 
Excretion 
Oral Rat Acute Toxicity (LD50) mol/kg 0.414 0.787 1.056 0.787 
Renal OCT2 substrate Yes/No No No No No 
CYP2D6 and CYP3A4 are two isoforms of Cytochrome p450, which is a crucial de-
toxification enzyme of the human body and responsible for changing the pharmacokinet-
ics of drugs. Thus, the tested compounds should be inactive (Tables 4–6). In terms of me-
tabolism, we found that all compounds act as a non-inhibitor of the cytochrome p450, 
which means that the molecule will not restrict the biotransformation of the drug metab-
olized by the CY2D6 enzyme and the CYP1A2 enzyme. Furthermore, renal OCT2 is an 
organic cation transporter 2, which plays a crucial role in renal clearance and disposition 
of drugs. Thus, tested compounds should not act as inhibitors of OCT2 and has to be in-
active during experiments.  
Table 6. The ADME results of 2DG and analogues. 








Water solubility log mol/L −0.512 −1.987 −1.654 −1.376 
Caco2 permeability Log 10−6 cm/s 1.559 1.985 1.654 1.098 
Intestinal absorption (human) %(Absorbed) 86.433 86.983 87.984 86.764 
Skin Permeability logKp −3.41 −3.98 −2.34 −2.75 
Distribution 
Fraction unbound (human) logL/Kg 0.916 0.914 0.158 0.985 
BBB permeability logBB −0.043 −0.025 −0.265 −0.265 
CNS permeability logPS −3.434 −3.254 −3.214 −3.147 
Metabolism 
CYP2D6 Yes/No No No No No 
CYP1A2 Yes/No No No No No 
Excretion 
Oral Rat Acute Toxicity (LD50)  mol/kg 1.153 1.258 1.245 1.452 
Renal OCT2 substrate Yes/No No No No No 
In excretion, we found that all compounds are inactive for renal OCT2 inhibitors, 
while the predicted LD50 value of these compounds are ˃500 mg/kg, suggesting that these 
compounds do not possess acute oral toxicity at lower doses (Tables 4–6). Important in-
formation obtained from SwissADME was the computed LD50 dose in a rat model. By 
comparing the LD50 doses, a compound with a lower dose was found to be more lethal 
than the compound with a higher LD50. From our observation, all compounds possess 
higher LD50 values (Tables 4–6). The physiochemical properties showed that all com-
pounds, which are analogues of GLC, BG6, and 2DG acquiring drug-like properties, can 
be good inhibitors of human HKII protein when tested in vitro. 
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3.1.3. Toxicity Test 
The toxicity test in this study was conducted by using the Pro Tox-II program. The 
prediction of compound toxicities is an important part of a drug design development pro-
cess. Computational toxicity estimations are not only faster than the determination of toxic 
doses in animals, but may also help reduce the amount of animal experiments. ProTox-II 
incorporates molecular similarity, fragment propensities, most frequent features, and 
(fragment similarity-based CLUSTER cross-validation) machine-learning, based on a total 
of 33 models for the prediction of various toxicity endpoints such as acute toxicity, hepa-
totoxicity, cytotoxicity, carcinogenicity, mutagenicity, immunotoxicity, adverse outcomes 
(Tox21) pathways and toxicity targets [45]. Acceptable toxicity value of GLC, BG6, and 
2DG analogues have been tabulated in Tables 7, 8, and 9, respectively. The toxicity has 
been classified into five classes: Class I: fatal if swallowed (LD50 ≤ 5), Class II: fatal if swal-
lowed (5 < LD50 ≤ 50), Class III: toxic if swallowed (50 < LD50 ≤ 300), Class IV: harmful if 
swallowed (300 < LD50 ≤ 2000), Class V: may be harmful if swallowed (2000 < LD50 ≤ 
5000), and Class VI: non-toxic (LD50 > 5000). Toxicity is proven essential in examining 
compounds for potential inclusion into drug development. The aim of toxicity studies is 
to ensure safety of the chemical compounds before they can be used as drugs or during 
clinical trials, as well as to determine the toxic effects of test substances [46]. In several 
experiments, different types of toxicity tests (acute toxicity, sub-acute toxicity, and chronic 
toxicity studies) have been conducted to characterize the possible toxic effects of drugs 
that can range from minor to critical [46,47]. 
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The Pro-tox-II software utilizes the consensus method to determine the values of dif-
ferent compounds by using different tests end-point analysis approaches, where LD50 
and LC50 values are exhibited for each compound (Tables 7–9). A smaller value indicates 
a more toxic compound and vice versa. According to the data analysis results obtained in 
the present study, most of the compounds that were similar to 2DG were toxic, but, in 
contrast, the toxicity of the top-ranked analogues of GLC exhibited non-toxic effects. 
Moreover, the analogues of BG6 were predicted to be non-toxic. It should also be noted 
that all examined compounds were negative for mutagenicity. As already mentioned pre-
viously, 2DG is a known inhibitor of HKII, but it has shown a toxic effect in in in vitro 
analysis [19,20], which highlighted the urgency to search for compounds that can be de-
veloped into a potent HKII inhibitor, which are non-toxic and safe to be administered as 
medications. 
3.2. Structure-Based Screening 
Structure-based virtual screening (SBVS) is an impactful experiment instrumental for 
fast and cost-effective lead discovery and optimization. The aim of this process is to un-
derstand the three-dimensional structure of the biological target at a molecular level [48]. 
Structure-based screening states the interaction of protein-ligand binding, where the 
mode of the binding complex can be predicted through docking and scoring functions, 
that comprise a two-step calculation to calculate the free binding energy of complex and 
exploring the conformational space of a protein and ligand complex [48]. The advantages 
of SBVS are time-saving and cost effective. There is no need for physical existences of the 
molecule and there are available free access software and web tools for conducting SBVS 
[48,49]. There are some disadvantages too. SBVS can generate a false positive and a false 
negatives result, as some tools work in specific cases and not in general, while it is also 
difficult to predict the accurate binding positions [49]. 
In this experiment, the crystal structure of human HKII from the Protein Data Bank 
(PDB ID: 2NZT) was prepared for molecular docking analysis by protein optimization 
and energy minimization. Additionally, all heteroatoms and ligands, which were already 
in a complex with the protein, were removed, because they can affect the docking process. 
HKII consists of two protein chains with two domains each. All 12 compounds were 
docked sequentially in each terminal of both chains, even though the two chains are ho-
modimers. This was done to observe variations in the binding energy and hydrogen bond 
numbers between the two chains, allowing us to determine which of the two was the best 
for the subsequent simulation procedure. In this study, we have conducted a docking pro-
cedure on the N-terminal of chain A because several studies have suggested that the N-
terminus (residues 1-475) contains more catalytic sites [35]. Our analysis involved docking 
12 compounds with the selected catalytic residues for each of the query molecules (2DG, 
GLC, and BG6). All the top-ranked molecules were successfully docked in the catalytic 
site of human HKII. 
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The top-ranked analogues of GLC, known as compound 10, compound 26, and com-
pound 58, had binding energies of −7.2, −7.0, and −6.10 kcal/mol, respectively, whereas the 
binding energy of GLC itself was −7.2 kcal/mol on the N-terminus of Chain A (Table 10). 
As described previously, the binding energy required for either chain of the HKII homodi-
mer was similar. Among all analogues of GLC, compound 10 exhibited the best binding 
energy (−7.0 kcal/mol) and took part in seven hydrogen bonds with residues Lys173, 
Asn208, Asp209, Glu260, Phe156, and Gln291 on HKII (Figure 2A). This closely resembles 
the query molecule GLC, which has a binding energy of −7.2 kcal/mol and takes part in 
six hydrogen bonds with residues Glu260, Lys173, Asp209, and Asn235 on HKII (Figure 
2B). However, compound 10 exhibited the best binding characteristics of the tested GLC 
analogues and might act as a potential inhibitor of HKII.  
The analogues of BG6, known as compound 30, compound 36, and compound 38, 
exhibited binding energies of −7.8, −7.4, and −7.0 kcal/mol, respectively, compared to BG6 
itself, which has a binding energy of −7.9 kcal/mol (Table 11). Compound 30 was chosen 
as the analogue with the best binding characteristics because it had the lowest binding 
energy value (−7.8 kcal/mol) and forms eleven hydrogen bonds, with Gly87, Asn89, 
Thr232, Arg91, Asp84, and Lys173 (Figure 3A). BG6 forms up to six hydrogen bonds with 
Lys173, Asn208, Gln291, Asp209, Thr233, Pro157, and Gly87 (Figure 3B). Therefore, the 
compound with the best binding characteristics among BG6 analogues was compound 30, 
which may be a potential inhibitor of HKII.  
The 2DG analogues, known as compound 1, compound 4, and compound 31, exhib-
ited binding energies of −6.8, −6.3, and −6.3 kcal/mol, respectively, as shown in Table 12. 
It should be noted that compound 1 exhibited a relatively low binding energy (−6.8 
kcal/mol), despite forming four hydrogen bonds with Asn208, Asp209, Thr172, Glu294, 
Thr232, and Lys173 (Figure 4A), compared to the binding energy of 2DG (−6.0 kcal/mol), 
which forms eight hydrogen bonds with Asn208, Asp209, Thr172, Glu294, Lys173, Glu260, 
and Phe156 (Figure 4B). Therefore, compound 1 was selected for further inhibition analy-
sis due to its relatively high binding affinity, compared to the other analogues of 2DG, 
and 2DG itself. 
Table 10. The top molecules, which are analogues of GLC, were ranked, according to their binding energy. The binding 
energy of GLC is also shown. 
ZINC ID 
Binding Energy (Kcal/mol) 
Chain A Terminal N 
Hydrogen Bond 
Number 
Chain A Terminal N 
Catalytic Residue 
GLC (−7.2)  6 Glu260, Lys173, Asp209, Asn235 
3956760 
Compound 10 
(−7.2)  7 Glu260,Gln291,Phe156,Asn208 ,Lys173,Asp209 
16159409 
Compound 26 
(−7.0)  5 Ser155, Asp209, Asn208,Lys173,Glu294 
3809846 
Compound 58 
(−6.10)  2 Asp209, Asn209, Ser155 
Table 11. The top molecules, which are analogues of BG6, were ranked according to their binding energy. The binding 




Chain A, Terminal N 
Hydrogen Bond 
Number 
Chain A Terminal N 
Catalytic Residue 
BG6 (−7.9)  6 




(−7.8)  11 Gly87, Asn89, Thr232, Arg91, Asp84, Lys173 





(−7.4)  9 Asp84, Thr88, Thr323, Asn89 
1576959 
Compound 38 
(−7.0)  5 Asn89, Thr88, Ser449 
Table 12. The top molecules, which are analogues of 2-DG, were ranked according to their binding energy. The binding 




Chain A Terminal N 
Hydrogen Bond 
Number 
Chain A Terminal 
N 
Catalytic Residue 
2DG (−6.0)  8 Asn208, Asp209, Thr172, Lys173, Glu294, Glu260, Phe156 
86652948 
Compound 1 
(−6.8)  4 Asp209, Asn208, Glu294, Thr172, Thr232, Lys173 
86991606 
Compound 4 
(−6.3)  3 Asp209, Asp84, Gly87, Thr88, Asp413, Thr232 
86991603 
Compound 31 
(−6.3)  1 Asp413, Asp84, Asp209 
Previous studies have attempted to use molecular docking approaches to identify 
small molecule inhibitors of dengue virus proteins. For example, Lim and colleagues [50] 
attempted to identify NS5 methyltransferase (MTase) inhibitors using a molecular dock-
ing approach. NS5 is a non-structural viral protein located on the dengue virus surface 
that assists in viral replication. Hence, it has been proposed as a drug target, with ribavirin 
triphosphate (RTP) and S-adenosyl-L-methionine (SAM) acting as query molecules. Lim 
and colleagues reported that compounds SPH1-103799, SPH1-101-102, and 28SPH1-115-
917 had the highest binding affinities of −11.4 kcal/mol, −11.4 kcal/mol, and −10.0 kcal/mol, 
respectively [50]. In this study, AutoDock Vina and EDULISS (Edinburgh University Lig-
and Selection System) were used for structure-based and ligand-based screening, respec-
tively. Another study by Wang and colleagues used four-stage computational high-
throughput screening to find a small molecule directed against the dengue virus envelope 
protein (E protein) [51]. The 23 highest ranking compounds in their analysis were selected 
based on the E protein binding site from three NIC libraries and were subsequently tested 
for antiviral activity in a biological assay. One compound, PO2, was found to inhibit viral 
reproduction.  
Thus, extensive research on the dengue virus has been conducted using molecular 
docking approaches [50–57]. However, it is important to note that all of the previously 
mentioned literature reported inhibitors which were developed based on viral proteins. 
There are plenty of in silico research on viral proteins were not fruitful for the development 
of dengue drug. Thus, in this research, we focused on human protein as a drug target. 
Overall, structure-based processes, such as molecular docking, provide a good approxi-
mation of protein-ligand binding affinity and help to identify the best candidates for fur-
ther inhibition studies in antiviral drug development. 




Figure 2. The chain A, N-terminal (red colour) and C-terminal (blue colour) of HKII was indicated in ribbon representation 
and the black circle indicates the catalytic site, where GLC and its analogues were docked. (A) Compound 10, which has 
formed one H bond with Gln291, Asp209, Phe156, and two H bond formed with Lys173, Asn208, and Glu260. (B) Mean-
while, the catalytic residue Lys173 has shown three H bonds, Asp209 with one, Asn235 with one, and Glu260 with one H 
bond, each formed with GLC. 
 




Figure 3. The chain A and N-terminal (red colour) and C-terminal (Blue colour) of HKII was indicated in a ribbon repre-
sentation and a black circle indicates the catalytic site, where BG6 and its analogues were docked. (A) Compound 30 has 
formed one H bond with a catalytic residue Asn89 and Arg91, while Thr232, Lys173, and Gly87 formed two H bonds and 
Asp formed three H bonds with compound 30. (B) Meanwhile, BG6 has formed one H bond with each residue Gln291, 
Asn209, Asp208, Thr233, and Lys173. 
 




Figure 4. The chain A and N-terminal (red color) and C-terminal (Blue color) of HKII was indicated in a ribbon represen-
tation and the black circle indicates the catalytic site, where 2DG and its analogues were docked. (A) Compound 1 formed 
four H bonds with catalytic residues Thr232 and Asn208. (B) Meanwhile, 2DG has formed one H bond with each residue 
Glu294, Asn208, and Thr232, while two H bonds formed with Lys173, Asp209, and Phe156. 
3.3. Molecular Dynamics Simulation 
The structural deviations and stability of HKII docked with compound 1, compound 
10, and compound 30, which are analogues of 2DG, GLC, and BG6, respectively, were 
assessed by 20 ns of MD simulation using GROMACS 4.6.5 programme. The stability of 
the protein-ligand complex was observed by measuring the root-mean-square deviation 
(RMSD) of each trajectory obtained in an MD simulation with respect to their position in 
the reference frame. The RMSD of all selected compounds fit into the HKII protein during 
the 20 ns period of dynamics simulation studies that are shown in Figures 5, 7, and 8. 
Ismail and Jusoh confirmed that RMSD determines the deviation in the average distance 
of the atomic structure movement in complexes, where generally the threshold of RMSD 
is 2Å [58]. The complex structure namely HKII-2DG, HKII-BG6, and HKII-GLC were used 
as references and comparison. Throughout the simulation, the complex HKII-Compound 
1 and HKII-2DG were seen equilibrated and their protein backbones were in minimal de-
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1 showed a slight fluctuation compared to the reference HKII-2DG complex toward the 
end of the simulation with the RMSD values consistent at ±0.5Å (Figure 5A), indicating 
that the interaction of HKII with compound 1 was comparable to 2DG. The HKII-2DG and 
HKII-compound 1 complexes were snapshots at one point of production simulation and 
both structures were superimposed to assess the ligand-binding topology as in Figure 5C. 
Both substrates were seen in a similar coordination, thus portraying the same level of in-
hibition towards the enzyme. The binding interaction of the HKII-compound 1 and HKII-
2DG complexes were closely monitored and differentiated along the simulation trajectory. 
For root mean square fluctuation (RMSF), each amino acid fluctuation of HKII for com-
pound 1 was in a similar pattern with reference compound 2DG (Figure 5B). No notewor-
thy changes were seen for the movement of the amino acids and the compounds did not 
disrupt the structural integrity of HKII. 
  





Figure 5. (A) The backbone RMSD of HKII-2DG (black) and HKII-compound 1(red) complexes shown during 20 ns of the 
MD simulation. (B) Residue RMSF of HKII-2DG and HKII-compound1 complexes generated during the trajectory period 
of 20 ns of the MD simulation. (C) Superimposition of the trajectory structure at 10 ns and 20 ns of MD simulations. The 
protein was presented in a cyan-coloured ribbon format. Snapshots of superimposed ligand 2DG (red) and compound 
1(blue) located in a ligand binding site. 
The binding stabilities of the protein-compound complexes were monitored during 
the trajectory period of the MD simulations. The stabilities of the protein-compound com-
plexes were evaluated by calculating the H bond profiles using the g, h bond tool of 
Gromacs [58,59]. The binding analysis revealed that the complex of 2DG in HKII had 
formed an average of six hydrogen bonds higher than the HKII-compound 1 complex 
(three hydrogen bonds) over the simulation time (Figure 6B,C). Figure 6B,C have shown 
the extracted trajectory of HKII-2DG and HKII-compound 1 at 20 ns, where compound 1 
bind with HKII by three H bond with catalytic residue of Asp84, Asp209, and Asp413, 
while the reference compound 2DG showed six H bonds with residue Asp84, Asn89, 
Asp209, Thr232, Thr88, and Ser415 (Figure 6B,C). This analysis has suggested that 2DG 
has a strong interaction with HKII in the dynamic condition during MD simulation. How-
ever, the formation of H bonds for compound 1 are lower than 2DG, but the compound 
consistently bound in the active site of HKII stably projected the active site vicinity. An-
other useful analysis is a distance calculation between the HKII and selected compounds. 
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the ligand-protein have to be as close as possible. Figure 6B,C depict the distance between 
HKII and compound 1 and reference molecule 2DG, which were 1.09Å and 1.03Å, respec-




Figure 6. (A) Total number of hydrogen bond interactions between HKII and 2DG (black) and HKII and compound 1 
(red). Snapshots of complex (B) HKII-2DG and (C) HKII-compound 1 were extracted from the trajectory at 20 ns. HKII-
2DG has shown six H bonds. Two formed with Thr232 and Asp413, one formed with Asn89, one formed with Asp84, and 
two formed with Thr88, Ser415. The HKII-compound 1 has shown three H bonds. Three formed with Asp413, Asp84, and 
Asp209. The distance between HKII and 2DG (cyan), compound 1(cyan) are, on average, 1.03Å and 1.09Å, respectively. 
For the HKII complex with BG6 and compound 30, both were stabilized over the 
simulation process while the complex HKII-GLC and HKII-compound 10 were less devi-
ated after 12 ns. Clearly, the structural dynamics of all complexes achieved stability before 
20 ns. For compound 30, the backbone of the HKII complex showed comparable devia-
tions with the reference complex, HKII-BG6, where their RMSD values were plateaued at 
±4.0Å (Figure 7A), indicating that both complexes were equilibrated and achieved a fa-
vourable binding conformation with each substrate. Meanwhile, for compound 10, the 
backbone of HKII-compound 10 showed a similar fluctuation with the HKII-GLC with an 
RMSD value of ±5.0 A° (Figure 8A), indicating that both complexes behaved similarly and 
performed stable interactions in the aqueous environment. 
2DG Compound 1 
B C 
A 
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All complexes (HKII-compound 30 and BG6, HKII-compound 10 and GLC) were 
snapshotted at 20 ns of MD production and superimposed with their reference structure 
to assess the binding location, as shown in Figures 7C and 8C. From the superposed im-
age, all substrates were in a close orientation with a reference and predicted to effectively 
inhibit HKII through a strong binding interaction. For RMSF, each amino acid fluctuation 
in HKII for compound 30 and compound 10 were in a similar pattern with their references 
BG6 and GLC, respectively. No significant changes were seen for the movement of the 
amino acids and the substrates were not disrupting the structural integrity of HKII. 
  





Figure 7. (A) The backbone RMSD of HKII-BG6 (black) and HKII-compound 30 (red) complexes shown during 20 ns of 
MD simulation. (B) Residue RMSF of HKII-BG6 and HKII-compound 30 complexes generated during the trajectory period 
of 20 ns of MD simulation. (C) Superimpose of trajectory structure at 10 ns and 20 ns of MD simulations. The protein was 
presented in a cyan-coloured ribbon format. Snapshots of superimposed ligand BG6 (red) and compound 30 (yellow) 































Figure 8. (A) The backbone RMSD of HKII-GLC (black) and HKII-compound 10 (red) complexes shown during 20 ns of 
MD simulation. (B) Residue RMSF of HKII-GLC and HKII-compound 10 complexes generated during the trajectory period 
of 20 ns of the MD simulation. (C) Superimpose of trajectory structure at 10 ns and 20 ns of MD simulations. The protein 
was presented in a cyan-coloured ribbon format. Snapshots of superimposed ligand GLC (red) and compound 10 (blue) 
located in a ligand binding site. 
The binding analysis of the HKII-compound 30 revealed a higher average number of 
hydrogen bond (7 hydrogen bonds) per time frame during the MD simulation period (Fig-
ure 9A) compared to a hydrogen bond of the HKII-BG6 complex (five hydrogen bonds). 
The extracted trajectory of complex HKII-compound 30 has shown seven H bonds with 
Asp84, Thr88, Asn89, Thr232, Ser415, and Gly87 at 20 ns during the MD simulation, while 
the snapshot of complex HKII-BG6 has shown five H bonds formed with residues Asn208, 
Asp209, Lys173, and Gln291 at 20 ns of the MD simulation (Figure 9B, C). This analysis 
has suggested that compound 30 has strong interactions with HKII in the dynamic condi-
tion during MD simulation, compared to reference molecule BG6. However, compound 
30 and BG6 were consistently bound in the active site of HKII and stably projected the 
active site vicinity. The distance between compound 30 and BG6 with HKII were below 
1.05Å, which defines that their binding was strong during the simulation time with dis-
tance values mentioned in Figure 9B and 9C. 
Furthermore, compound 10 with HKII has formed an average of six hydrogen bonds, 
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Figures 10B,C have shown the extracted trajectory of HKII-GLC and HKII-compound 10 
at 20 ns, where GLC binds with HKII by four H bonds with catalytic residues Asp209 and 
Lys173, while compound 10 has shown six H bonds with a catalytic residue of Asn209, 
Lys173, Gln291, and Asp209 (Figure 10B,C). Thus, it can be said that compound 10 has 
more intermolecular interactions via hydrogen bonding and the compound was stably-
bound in the catalytic region of HKII, showing a high level of inhibition compared to the 
reference molecule GLC.  
  
  
Figure 9. (A) Total number of hydrogen bond interactions between HKII and BG6 (red), and HKII and compound 30 
(black). Snapshots of complex (B) HKII-BG6, and (C) HKII-compound 30 were extracted from the trajectory at 20 ns. HKII-
BG6 has shown five H bonds. Rwo formed with Asn208 and Asp209, and three formed with Gln291, Lys173, and Thr232. 
HKII-compound 30 has shown seven H bonds. Three formed with Asp84, Asn89, and Thr88. Four formed with Ser415, 
Gly87, and Thr232. The distance between HKII and BG6 (yellow), and HKII and compound 30 (yellow) have an average 
of 1.05Å. 
  
BG6 Compound 30 
B C 
A 





Figure 10. (A) The total number of hydrogen bond interactions between HKII and GLC (red), and HKII and compound 10 
(black). Snapshots of complex (B) HKII-GLC and (C) HKII-compound10 were extracted from the trajectory at 20 ns. HKII-
GLC has shown three H bonds. Two formed with Lys173 and one formed with Asp209. HKII-compound 10 has shown 
six H bonds. Four formed with Lys173 and Asp209 and two formed with Gln291 and Asn208. The distance between HKII 
and GLC (yellow), and HKII and compound 10 (yellow) are, on average, 2.00Å. 
The distance between HKII and GLC as well as compound 10 were, on average, 2.0Å, 
which defined that their binding was strong throughout the simulation period. Several 
studies have reported the discovery of dengue inhibitors against the viral proteins 
through the MD simulation process. Shanmugam and Gromiha (2016) have conducted 
insilico processes such as molecular docking to find potential inhibitors against RNA-de-
pendent RNA polymerase, which is essential for dengue viral replication. The researchers 
obtained quercetin derivatives, quercetin 3-(6''-(E)-pcoumaroylsophoroside)-7-rhamno-
side as a dengue polymerase inhibitor, where this finding was validated based on the sta-
bility of the enzyme and inhibitor by an MD simulation [59]. In another study, Shanmu-
gam and colleagues also identified, [2-(4-carbamoylpiperidin-1-yl)-2-oxoethyl] 8-(1,3-ben-
zothiazol-2-yl) naphthalene-1-carboxylate as a potent dengue viral polymerase inhibitor 
by maintaining the same simulation condition from the previous study [60]. Most of the 
inhibitors were identified through an MD simulation against viral replication proteins, 
GCL Compound 10 
B C 
A 
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such as non-structural protein 3 (NS3), NS5 methyltransferase, and also envelope protein 
(E) [58–64]. Currently, 18 million compounds were virtually-screened against dengue rep-
lication protein NS3, where the top five compounds have shown strong predicted binding 
affinity for the important catalytic residues of NS3 [65]. Eventually, the top five com-
pounds further went through the MD simulation to scrutinize the stability of selected 
compounds and NS3 protein throughout the simulation period [65]. In another study, 300 
commercial cyclic peptides were screened against NS5 methyltransferase where two lig-
ands, namely preproendothelin and urotensin II, were selected as the best inhibitors based 
on ligand-enzyme binding free energy and pharmacological prediction. Furthermore, it 
was confirmed that both ligands maintained a stable complex conformation with the en-
zymes throughout a 6-ns simulation period [64,66]. On the contrary, our findings were 
evaluated based on the stability of protein-ligand throughout the simulation period, 
where compound 1, compound 10, and compound 30, which are the analogues of 2DG, 
GLC, and BG6 respectively, have shown protein-ligand stability during the course of the 
simulation process.  
4. Conclusions  
There is an urgent need to design better inhibitors against the DENV, in which hu-
man hexokinase II (HKII) was proposed as an ideal target for anti-DENV drug develop-
ment. Precise and computationally-competent virtual screening can act as a potential step 
toward the future “on-shelf” dengue virus drugs. Consequently, we have identified a 
number of novel compounds by in silico screening of library of compounds from the 
USRCAT database using Auto Dock Vina docking programs. Docking results of the top 
three compounds for each reference molecule in our study have shown strong predicted 
binding affinity for the catalytically-important residues of HKII. Finally, compound 10, 
compound 30, and compound 1, which are the analogues of GLC, BG6, and 2DG, respec-
tively, have exhibited strong protein-ligand stability with RMSD ±5.0A°, ±4.0A°, and 
±0.5A throughout the simulation process. The effects of these compounds on the activity 
of HKII are currently being pursued in the subsequent structural and biochemical studies. 
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